Table 2 Genomic loci associated with breast cancer (P-value < 10−5).

From: BRCA1/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impacts

SNP

Chr

Position (hg19)

Nearest Genes (distance to gene)

Function

Risk Allele (fwd)

RAF in 1 kG Phase3a

Korean BRCAX cases (initial)

Asian high-risk cases (replication)

Meta-analysis

EAS

EUR

RAF in casesa

P-value

OR (95% CI)b

RAF in casesa

P-value

OR (95% CI)b

P-value

OR (95% CI)b

P hetero c

rs60538652

3

150473606

SIAH2

Intron

A

0.61

0.98

0.65

6.24.E-07

1.26 (1.15–1.38)

0.73

0.072

1.13 (0.99–1.28)

3.25.E-07

1.21 (1.13–1.31)

0.16

rs11154838

6

136290942

PDE7B

Intron

C

0.72

0.65

0.75

1.28.E-06

1.27 (1.15–1.40)

0.83

0.005

1.26 (1.07–1.49)

2.27.E-08

1.27 (1.17–1.38)

0.96

rs9383936

6

151944614

3′ of CCDC170 (2.3 Kb), 5′ of ESR1 (3.3 Kb)

Intergenic

A

0.31

0.08

0.34

1.01.E-10

1.35 (1.23–1.48)

0.34

1.05.E-06

1.3 (1.17–1.44)

6.35.E-16

1.33 (1.24–1.42)

0.58

rs10953105

7

93622247

BET1

3′ UTR

G

0.86

0.97

0.88

1.13.E-06

1.37 (1.21–1.56)

0.91

0.192

1.14 (0.94–1.38)

1.81.E-06

1.30 (1.16–1.44)

0.11

rs2350923

8

62605259

ASPH

Intron

T

0.72

0.70

0.76

7.75.E-07

1.28 (1.16–1.42)

0.27

0.750

1.02 (0.92–1.13)

0.250

1.14 (0.91–1.44)

0.00

rs78545330

9

21995941

CDKN2B-AS1

Intron

A

0.21

0.08

0.26

3.41.E-06

1.26 (1.14–1.39)

0.20

5.73.E-03

1.19 (1.05–1.35)

8.56.E-08

1.23 (1.14–1.33)

0.47

rs10814070

9

34129839

3′ of DCAF12 (3.1 Kb)

Intergenic

T

0.71

0.25

0.75

1.93.E-06

1.26 (1.15–1.39)

0.65

0.469

0.96 (0.87–1.07)

0.465

1.10 (0.85–1.44)

0.00

rs2912774

10

123348662

FGFR2

Intron

T

0.38

0.43

0.42

5.96.E-07

1.25 (1.14–1.36)

0.43

0.052

1.11 (1.00–1.21)

5.60.E-07

1.18 (1.10–1.25)

0.06

rs9418690

10

128809949

DOCK1

Intron

C

0.73

0.76

0.76

1.08.E-06

1.28 (1.16–1.41)

0.82

0.819

1.02 (0.85–1.23)

0.183

1.16 (0.93–1.44)

0.04

rs4964006

12

26770889

ITPR2

Intron

T

0.95

0.69

0.98

1.52.E-06

1.96 (1.49–2.58)

0.95

0.804

0.97 (0.76–1.24)

0.366

1.38 (0.69–2.75)

0.00

rs67129489

12

96016957

5′ of PGAM1P5 (26.0 Kb), 5′ of NTN4 (34.6 Kb)

Intergenic

G

0.13

0.32

0.15

9.31.E-07

1.36 (1.20–1.53)

0.06

0.976

1.00 (0.77–1.32)

0.226

1.20 (0.89–1.60)

0.05

rs278050

13

30436968

5′ of UBL3 (73 Kb)

Intergenic

C

0.19

0.23

0.21

3.89.E-06

1.28 (1.15–1.42)

0.19

0.050

1.13 (1.00–1.28)

1.64.E-06

1.22 (1.12–1.32)

0.14

rs4784227

16

52583143

TOX3

Intron

T

0.26

0.25

0.32

9.11.E-09

1.31 (1.19–1.44)

0.29

6.24.E-05

1.25 (1.12–1.39)

3.26.E-12

1.28 (1.20–1.38)

0.49

rs4969001

17

70980127

SLC39A11

Intron

T

0.89

0.96

0.86

6.53.E-06

1.32 (1.17–1.49)

0.89

0.041

0.85 (0.73–0.99)

0.780

1.06 (0.69–1.64)

0.00

rs73107564

20

36263775

Intergenic

A

0.89

0.81

0.89

1.81.E-07

1.43 (1.25–1.63)

0.87

0.541

0.96 (0.83–1.10)

0.432

1.17 (0.79–1.73)

0.00

  1. aRAF: risk allele frequency, EAS: East Asian, EUR: European.
  2. bOR: odds ratio, CI: confidence interval.
  3. cPhetero: P-value for heterogeneity. Fixed effect model was used if p-value for heterogeneity exceeds 0.05; otherwise random effect model was used.